Abvc Biopharma (ABVC) Total Liabilities (2010 - 2026)

Abvc Biopharma (ABVC) has reported Total Liabilities for 17 consecutive years, with $7.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 5.63% year-over-year to $7.1 million; the trailing twelve-month figure through Jun 2026 stood at $7.1 million (up 5.63% YoY), and the FY2025 full-year result was $7.8 million, up 13.92% from the prior year.
• Total Liabilities rose to $7.1 million in Q2 2026 per ABVC's latest filing, from $6.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $9.7 million in Q2 2023 and bottomed at $4.6 million in Q2 2022.
• Historically, Total Liabilities has averaged $6.8 million across 5 years, with a median of $6.7 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities plunged 46.51% in 2022, then soared 110.5% in 2023.
• Over 5 years, Total Liabilities stood at $6.3 million in 2022, then rose by 2.96% to $6.5 million in 2023, then grew by 4.36% to $6.8 million in 2024, then climbed by 13.92% to $7.8 million in 2025, then decreased by 8.16% to $7.1 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $7.1 million, $6.9 million, and $7.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.